Agents such as Trebananib used in a phase III cancer trial, demonstrated increased progression-free survival in ovarian cancer, highlighting its potential in advanced stages where TIE-1 overexpression is linked to poorer prognosis.383,384 Also, The VE-PTP inhibitor AKB-9778 has shown effectiveness in reducing edema and improving vision in retinal vascular diseases, supporting the therapeutic potential of TIE2 activation.385. Here, TIE1 is linked to ovarian carcinoma.